Cabaletta Bio Q3 2026 Results: Net Loss of $53.1M, Loss Widens
Cabaletta Bio is a late-stage clinical biotechnology company focused on autoimmune diseases, specifically advancing its Phase 1/2 RESET clinical trials for rese-cel. As of October 30, 2026, the company reported 215,720,392 shares of common stock outstanding and continues to incur significant losses to fund its R&D and manufacturing partnerships with Lonza and Cellares.
- Key figure
- Net loss $53.1M